Pages that link to "Q44507299"
Jump to navigation
Jump to search
The following pages link to Polymorphism of the 5-HT transporter and response to antidepressants: randomised controlled trial (Q44507299):
Displaying 32 items.
- Citalopram versus other anti-depressive agents for depression (Q24202141) (← links)
- From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatment (Q27015830) (← links)
- A mega-analysis of genome-wide association studies for major depressive disorder (Q29417093) (← links)
- A neurobiological hypothesis of treatment-resistant depression - mechanisms for selective serotonin reuptake inhibitor non-efficacy (Q33658525) (← links)
- Association between serotonin transporter polymorphisms (5-HTTLPR) and the MADRS Dysphoria, Retardation, and Vegetative Subscale scores in the treatment of depression (Q33806771) (← links)
- Adverse effects from antidepressant treatment: randomised controlled trial of 601 depressed individuals (Q33906501) (← links)
- Allowing for non-adherence to treatment in a randomized controlled trial of two antidepressants (citalopram versus reboxetine): an example from the GENPOD trial (Q34038812) (← links)
- Association of the 5-HTT gene-linked promoter region (5-HTTLPR) polymorphism with psychiatric disorders: review of psychopathology and pharmacotherapy (Q34316695) (← links)
- Genetic polymorphism in the serotonin transporter gene-linked polymorphic region and response to serotonin reuptake inhibitors in patients with premature ejaculation (Q34628110) (← links)
- Involving patients with depression in research: survey of patients' attitudes to participation (Q34711882) (← links)
- Are multiple physical symptoms a poor prognostic factor or just a marker of depression severity? Secondary analysis of the GenPod trial (Q35044690) (← links)
- Piccolo genotype modulates neural correlates of emotion processing but not executive functioning (Q35913903) (← links)
- Facilitated physical activity as a treatment for depressed adults: randomised controlled trial (Q36011963) (← links)
- Minimal clinically important difference on the Beck Depression Inventory--II according to the patient's perspective (Q36178420) (← links)
- Genome-wide approaches to antidepressant treatment: working towards understanding and predicting response (Q36973699) (← links)
- Genetics as a molecular window into recovery, its treatment, and stress responses after stroke (Q37088174) (← links)
- Systematic review and meta-analysis of serotonin transporter genotype and discontinuation from antidepressant treatment (Q37217494) (← links)
- Serotonin Transporter Polymorphism (5-HTTLPR) and Citalopram Effectiveness in Iranian Patients with Major Depressive Disorder (Q37229060) (← links)
- Stress-related depression: neuroendocrine, genetic, and therapeutical aspects (Q38016982) (← links)
- Pharmacogenetics of antidepressant drugs: an update after almost 20 years of research (Q38121519) (← links)
- Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapy (Q38154911) (← links)
- A randomised controlled trial assessing the severity and duration of depressive symptoms associated with a clinically significant response to sertraline versus placebo, in people presenting to primary care with depression (PANDA trial): study protoc (Q42634374) (← links)
- Pharmacogenetics of neural injury recovery (Q46852529) (← links)
- Progress in Elucidating Biomarkers of Antidepressant Pharmacological Treatment Response: A Systematic Review and Meta-analysis of the Last 15 Years (Q47666907) (← links)
- Association of 5-HTTLPR Polymorphism with the Nursing Diagnoses and the Achievement of Nursing Outcomes in Patients with Major Depression (Q47744358) (← links)
- SERT and NET polymorphisms, temperament and antidepressant response (Q48102826) (← links)
- Serotonin transporter gene hypomethylation predicts impaired antidepressant treatment response (Q48324504) (← links)
- Genetic predictors of antidepressant side effects: a grouped candidate gene approach in the Genome-Based Therapeutic Drugs for Depression (GENDEP) study (Q48372657) (← links)
- Does baseline fatigue influence treatment response to reboxetine or citalopram in depression? An open label randomized controlled trial (Q48765199) (← links)
- Evoked Culture and Evoked Nature: The Promise of Gene-Culture Co-Evolution Theory for Sociology (Q58643545) (← links)
- Quantifying between-cohort and between-sex genetic heterogeneity in major depressive disorder (Q64444721) (← links)
- What factors indicate prognosis for adults with depression in primary care? A protocol for meta-analyses of individual patient data using the Dep-GP database (Q95588626) (← links)